scholarly journals Understanding Dengue Virus Capsid Protein Interaction with Key Biological Targets

2015 ◽  
Vol 5 (1) ◽  
Author(s):  
André F. Faustino ◽  
Ivo C. Martins ◽  
Filomena A. Carvalho ◽  
Miguel A. R. B. Castanho ◽  
Sebastian Maurer-Stroh ◽  
...  
Keyword(s):  
Dengue Virus ◽  
Capsid Protein ◽  
Protein Interaction ◽  
Virus Capsid ◽  
Biological Targets ◽  
Virus Capsid Protein

scholarly journals Dengue Virus Capsid Protein Binding to Lipid Droplets and its Inhibition. towards a New Drug Target

2013 ◽  
Vol 104 (2) ◽  
pp. 415a
Author(s):  
Filomena A. Carvalho ◽  
Ivo C. Martins ◽  
Fabiana A. Carneiro ◽  
Iranaia Assunção-Miranda ◽  
André F. Faustino ◽  
...  
Keyword(s):  
Dengue Virus ◽  
Protein Binding ◽  
Capsid Protein ◽  
Drug Target ◽  
Lipid Droplets ◽  
Virus Capsid ◽  
New Drug ◽  
Virus Capsid Protein

Novel Peptides Derived from Dengue Virus Capsid Protein Translocate Reversibly the Blood–Brain Barrier through a Receptor-Free Mechanism

2017 ◽  
Vol 12 (5) ◽  
pp. 1257-1268 ◽  
Author(s):  
Vera Neves ◽  
Frederico Aires-da-Silva ◽  
Maurício Morais ◽  
Lurdes Gano ◽  
Elisabete Ribeiro ◽  
...  
Keyword(s):  
Dengue Virus ◽  
Capsid Protein ◽  
Blood Brain Barrier ◽  
Brain Barrier ◽  
Virus Capsid ◽  
Blood Brain ◽  
Virus Capsid Protein

Anti-HIV-1 Activity of pepRF1, a Proteolysis-Resistant CXCR4 Antagonist Derived from Dengue Virus Capsid Protein

2020 ◽  
Author(s):  
Iris Cadima-Couto ◽  
Alexandra Tauzin ◽  
João M. Freire ◽  
Tiago N. Figueira ◽  
Rúben D. M. Silva ◽  
...  
Keyword(s):  
Dengue Virus ◽  
Capsid Protein ◽  
Cxcr4 Antagonist ◽  
Virus Capsid ◽  
Anti Hiv ◽  
Virus Capsid Protein ◽  
Hiv 1

scholarly journals Nucleolin Interacts with the Dengue Virus Capsid Protein and Plays a Role in Formation of Infectious Virus Particles

2013 ◽  
Vol 87 (24) ◽  
pp. 13094-13106 ◽  
Author(s):  
C. A. Balinsky ◽  
H. Schmeisser ◽  
S. Ganesan ◽  
K. Singh ◽  
T. C. Pierson ◽  
...  
Keyword(s):  
Dengue Virus ◽  
Capsid Protein ◽  
Infectious Virus ◽  
Virus Capsid ◽  
Virus Particles ◽  
Virus Capsid Protein

Production and characterization of anti-dengue capsid antibodies suggesting the N terminus region covering the first 20 amino acids of dengue virus capsid protein is predominantly immunogenic in mice

2009 ◽  
Vol 154 (8) ◽  
pp. 1211-1221 ◽  
Author(s):  
Chunya Puttikhunt ◽  
Prapapun Ong-ajchaowlerd ◽  
Tanapan Prommool ◽  
Sutha Sangiambut ◽  
Janjuree Netsawang ◽  
...  
Keyword(s):  
Amino Acids ◽  
Dengue Virus ◽  
Capsid Protein ◽  
Virus Capsid ◽  
N Terminus ◽  
Virus Capsid Protein

scholarly journals Dengue Virus Capsid Protein Usurps Lipid Droplets for Viral Particle Formation

2009 ◽  
Vol 5 (10) ◽  
pp. e1000632 ◽  
Author(s):  
Marcelo M. Samsa ◽  
Juan A. Mondotte ◽  
Nestor G. Iglesias ◽  
Iranaia Assunção-Miranda ◽  
Giselle Barbosa-Lima ◽  
...  
Keyword(s):  
Dengue Virus ◽  
Capsid Protein ◽  
Lipid Droplets ◽  
Viral Particle ◽  
Particle Formation ◽  
Virus Capsid ◽  
Virus Capsid Protein

scholarly journals Drug Repurposing Commonly Against Dengue Virus Capsid and SARS-CoV-2 Nucleocapsid: An in Silico Approach

2020 ◽  
Author(s):  
Debica Mukherjee ◽  
Rupesh Roy ◽  
UPASANA RAY
Keyword(s):  
Dengue Virus ◽  
Capsid Protein ◽  
In Silico ◽  
Rna Binding ◽  
Drug Repurposing ◽  
Virus Capsid ◽  
Approved Drugs ◽  
Full Swing ◽  
Fda Approved Drugs ◽  
Virus Capsid Protein

<p></p><p>In the middle of SARS-CoV-2 pandemic, dengue virus (DENV) is giving a silent warning as the season approaches nearer. There is no specific antiviral against DENV for use in the clinics. Thus, considering these facts we can potentially face both these viruses together increasing the clinical burden. The search for anti-viral drugs against SARS-CoV-2 is in full swing and repurposing of already ‘in-use’ drugs against other diseases or COVID-19 has drawn significant attention. Earlier we had reported few FDA approved anti-viral and anti-microbial drugs that could be tested for binding with SARS-CoV-2 nucleocapsid N terminal domain. We explored the possibility of interactions of the drugs screened for SARS-CoV2 with Dengue virus capsid protein. We report five FDA approved drugs that were seen to be docking onto the SARS-CoV-2 nucleocapsid RNA binding domain, also docking well with DENV capsid protein on the RNA binding site and/or the capsid’s membrane fusion domain. Thus, the present study proposes these five drugs as common antiviral candidates against both SARS-CoV-2 and DENV although the <i>in silico</i> study is subject to further validations.</p><br><p></p>

Nuclear localization of dengue virus capsid protein is required for DAXX interaction and apoptosis

2010 ◽  
Vol 147 (2) ◽  
pp. 275-283 ◽  
Author(s):  
Janjuree Netsawang ◽  
Sansanee Noisakran ◽  
Chunya Puttikhunt ◽  
Watchara Kasinrerk ◽  
Wiyada Wongwiwat ◽  
...  
Keyword(s):  
Dengue Virus ◽  
Capsid Protein ◽  
Nuclear Localization ◽  
Virus Capsid ◽  
Virus Capsid Protein
Sign in / Sign up

Export Citation Format

Share Document